Brief: Veru Reports Positive Safety Results From Phase 2B Quality Study
28/05/2025 12:44
May 28 (Reuters) - Veru Inc VERU.O: VERU REPORTS POSITIVE SAFETY RESULTS FROM PHASE 2B QUALITY STUDY: ENOBOSARM ADDED TO SEMAGLUTIDE LED TO GREATER FAT LOSS, PRESERVATION OF MUSCLE, AND FEWER GASTROINTESTINAL SIDE EFFECTS COMPARED TO SEMAGLUTIDE ALONE VERU INC - TOPLINE DATA FOR PHASE 2B EXTENSION STUDY EXPECTED IN SECOND QUARTER VERU INC: TRIAL MET ITS PRESPECIFIED PRIMARY ENDPOINT VERU INC - REQUESTS END OF PHASE 2 MEETING WITH FDA FOR PHASE 3 REGULATORY CLARITY Source text: ID:nGNX3V5L3M Further company coverage: VERU.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Veru
See all newsUS STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Oppenheimer upbeat on Veru, says 'come for the lean mass, stay for the muscle function'
Veru Inc. reports results for the quarter ended June 30 - Earnings Summary